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Accelerating the translational medicine cycle: the 
Academia Europaea pilot
To the Editor—Translational Medicine 
(TM) is among the main challenges of the 
21st century; its development is essential 
for the application of scientific results for 
community benefit.
Although several developments have 
been achieved in the field, there is still 
room for improvement in implementing 
scientific results in healthcare. More than 
1.4 million articles are published each 
year, as reported on PubMed; however, 
much of this knowledge is not applied in 
everyday practice. Based on a report from 
the European Commission’s European 
Statistical Office, around 1.7 million 
people under 75 years of age die in Europe 
every year, but 1.2 million of these deaths 
could have been avoided through effective 
primary prevention and public-health 
intervention1.
The Academia Europaea, one of 
the leading advisory bodies of the 
European Commission, thus initiated 
the development of a new TM model 
that facilitates and accelerates the 
application of scientific knowledge for 
community benefit2. The new cycle 
model equally focuses on healthcare, the 
acquisition of new scientific findings, the 
digestible summation of results, and the 
communication of scientific knowledge 
to all stakeholders, including patients, 
healthcare professionals, pharmaceutical 
companies and policymakers. The 
model has been piloted at the Centre for 
Translational Medicine at the University 
of Pécs (UP-CTM) in Hungary, with great 
success, which made UP-CTM one of the 
most efficient and visible centers for TM  
in Eastern and Central Europe within  
five years.
The TM cycle model in healthcare was 
trialed in an eight-bed UP-CTM patient 
care unit that focused on managing acute 
pancreatitis. Patient coordinators, clinical 
research administrators, PhD students, 
nurses, and junior and senior doctors 
joined forces in the day-to-day work. 
This team ensured the application of 
available evidence-based guidelines and, 
notably, built up activities for healthcare 
delivery science—for example, the team 
enrolled patients in clinical trials and 
patient registries, and organized and 
analyzed the diagnostic and treatment 
pathways. In a year, we achieved a 
two-day reduction in the length of 
hospitalization per patient, a marked 
decrease in antibiotics administration, 
and a two-thirds drop in mortality. Due 
to the healthcare-delivery-science activity, 
patient-care costs also fell by 25%  
(ref. 3) (Fig. 1a).
The model was subsequently tested in 
two other hospitals. At the Szent György 
University Teaching Hospital of Fejér 
County (Székesfehérvár, Hungary), a 
similar healthcare delivery science–based 
patient care unit for acute pancreatitis was 
launched. As a result, the use of antibiotics 
substantially decreased. The duration of 
hospitalization dropped by an average of 
one day per patient (Fig. 1b). At the Heim 
Pál National Pediatric Institute (Budapest, 
Hungary), a scientifically constructed 
cystic-fibrosis registry, which also 
examined glucose metabolism in detail, 
facilitated the early diagnosis of diabetes 
mellitus in 14% of the patients; these  
would have been missed by the previous 
system. In addition, nine children were 
identified as having impaired glucose 
tolerance; this may allow earlier diagnosis 
and treatment of established cystic 
fibrosis–related diabetes.
After the projects involving acute 
pancreatitis, we broadened our patient 
registries and clinical trials to a wide range 
of medical disciplines (Fig. 1c,d). Notably, 
these clinical databases and biobank 
samples substantially added to the 300 
publications by UP-CTM over the five 
years, which may substantially contribute 
to the implementation of scientific results 
for community benefit. The outstanding 
networking is well illustrated through 
UP-CTM’s joint publications involving  
more than a thousand researchers in the  
five years (Fig. 1e).
To support patient care, scientific 
activity and communication, we set up an 
interdisciplinary unit at the outset with 
several different disciplines, including 
patient coordination, biostatistics, 
informatics, data management, 
artificial intelligence, legal support 
and communication. Notably, the unit 
accelerated scientific activity, supported 
patient care and communication, and 
created 51 jobs with new professional 
content by the end of the five years, which 
is extremely important in a century during 
which the demand for professionals is 
decreasing in numerous fields (Fig. 1f).
A shift was necessary for the academic 
field and communication as well. Medical 
professionals must understand scientific 
results to deliver high-quality patient care; 
therefore, our center developed a new 
‘learning by doing’ education module in 
which 45 young physicians learned the 
scientific methodology. The program’s 
strength is emphasized by the fact that 
doctors from ten different cities in four 
countries participated in the training 
program. At the same time, we developed 
a complex Clinical Research Administrator 
training program accredited and tested in 
the fifth year. During this period, printed 
educational materials and online educational 
videos were made available for healthcare 
professionals; these have been particularly 
useful during the COVID-19 pandemic. 
Grant committees also recognized the 
potential of the TM cycle approach (Fig. 1g).
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For the best implementation of scientific 
results in practice, information must 
also be disseminated to non-medical 
people. With the onset of the COVID-19 
pandemic, we immediately established the 
Translational Action and Research Group 
against Coronavirus (KETLAK) to reduce 
the coronavirus-induced health damage 
and deaths. Two extensive reports were 
presented directly to Hungary’s national 
epidemiological policymaking body by 
our KETLAK group in April 2020, which 
facilitated the country’s management of 
the first wave of the COVID-19 pandemic 
with excellent results4. We launched the 
PROACTIVE-19 study, providing health 
education to the community from the 
outbreak of this pandemic5. We had 
approximately 150 media appearances, 
which also played an essential role in 
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Fig. 1 | Five-year results of implementation of the academia europaea tM cycle model. a, total mortality and mortality from moderate acute pancreatitis 
(MAP), moderately severe acute pancreatitis (MsAP) and severe acute pancreatitis (sAP) before (left) and after (right) implementation of the uP-CtM 
patient care unit. b, Antibiotics use for acute pancreatitis before and after implementation of the uP-CtM patient care unit; pie charts indicate the proportion 
of patients who received antibiotics (light blue) or not (teal). c,d, Clinical databases and biobank samples (c) and collaborations (d) included in the uP-CtM 
after the initial five-year period. e, Yearly scientific output (horizontal axes) before and after implementation of the uP-CtM. D1, publications in the top 10% 
of the journals; Q1–Q4, publications in the first quartile (top 25%) and second, third and fourth quartiles of the journals, respectively. f, Components of the 
interdisciplinary unit of the uP-CtM. It, information technology; AI, artificial intelligence. g, Educational efforts and support of the uP-CtM. h,i, Outreach of 
the uP-CtM to policymakers (h) and the community (i) during the COVID-19 pandemic.
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Of course, we concentrated not only on 
COVID-19 but also on other diseases. 
In total, we helped the population 
with 31 patient-education videos, 43 
social-media appearances and 13 printed 
patient-information leaflets (Fig. 1i).
What does the future hold? It is hard 
to predict, but it is certainly up to us. We 
strongly believe that disseminating the 
model and highlighting the successes it 
achieves can help. It is an excellent sign 
that Semmelweis University has already 
invited us to build the TM cycle in Budapest; 
moreover, several European and American 
universities have already expressed interest 
in introducing the TM cycle model or 
further developing their existing models. 
Is this model perfect? Certainly not, but it 
represents a considerable advance. ❐
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A French cohort for assessing COVID-19 vaccine 
responses in specific populations
To the Editor—The COVID-19 vaccination 
campaign started in France on 27 December 
2020. It has been rolled out in different 
priority phases according to the risk of 
developing a severe form of COVID-
19 and the risk of being exposed to the 
causative coronavirus SARS-CoV-2. By 5 
May 2021, four vaccines against COVID-
19 were approved by the European 
Medicines Agency and were available in 
France: COMIRNATY (the COVID-19 
mRNA vaccine BNT162b2; BioNTech–
Pfizer); COVID-19 Vaccine Moderna 
(mRNA-1273; Moderna); VAXZEVRIA 
(ChAdOx1-nCoV19; AstraZeneca–Oxford 
University); and COVID-19 Vaccine 
Janssen (Ad26.COV2.S; Janssen). Specific 
populations are defined as people at risk 
of developing severe forms of the disease 
and in whom the immunogenicity and 
efficacy of vaccines against that disease may 
differ from that of the general population 
(e.g., recipients of solid-organ transplants 
or patients undergoing hemodialysis).
The safety, immunogenicity and efficacy 
of vaccines in specific populations, which 
are heterogeneous groups of patients, are 
affected by the nature and intensity of the 
underlying disease(s), the age of the patient 
and any other treatments the patient is 
taking, and are possibly affected by the 
vaccine platform used. So far, no or only 
limited data on specific populations are 
available from published results of phase 
3 trials of authorized vaccines against 
COVID-19. Initial immunogenicity 
data available for some of these specific 
populations showed low antibody responses 
to the SARS-CoV-2 spike protein in patients 
who received solid-organ transplantation1–4, 
patients undergoing hemodialysis5,6, patients 
receiving chemotherapy or immunotherapy 
for solid cancer or hematologic 
malignancies7,8, and patients receiving 
infliximab for inflammatory bowel disease9. 
Most of these studies reported small  
sample sizes.
To assess the immune response of 
COVID-19 vaccines in different specific 
populations, INSERM (Institut National 
de la Santé et de la Recherche Médicale) 
and ANRS-MIE (Agence Nationale 
de Recherche sur le Sida–Maladies 
Infectieuses Emergentes), in collaboration 
with the COVIREIVAC network, ten 
national disease-specific societies and 
seven patients’ associations (France Rein, 
Transhépate, ARSEP Foundation, CNAO, 
FFD, EGMOS and TRT5 CHV), launched, 
on 25 March 2021, the ANRS0001S 
COV-POPART study (ClinicalTrials.
gov NCT04824651). COV-POPART 
is a national multi-center prospective 
multi-cohort study of specific populations 
vaccinated against COVID-19 that aims to 
include 10,700 patients.
Patients with solid cancer (n = 800), 
solid-organ transplantation (n = 700), 
hematopoietic stem cell transplantation 
(n = 350), chronic renal failure with 
or without dialysis (n = 350), multiple 
sclerosis or neuromyelitis optica spectrum 
disorders (n = 600), autoimmune 
inflammatory rheumatic diseases (n = 600), 
systemic autoimmune diseases (n = 600), 
hypogammaglobulinemia (n = 300), obesity 
(1,400), diabetes mellitus (n = 1,400) and/
or infection with human immunodeficiency 
virus (n = 1,400) will be included. All adults 
affected by at least one of these chronic 
conditions, without a history of COVID-19  
and not yet vaccinated, will be included 
in one of the 35 participating centers, 
which represent more than 250 clinical 
sites. A control group without any of the 
above-mentioned underlying conditions 
will also be included (n = 1,850; 18–74 
years of age (n = 1,400) and ≥75 years of 
age (n = 450)).
The main objective will be to analyze 
the humoral immune response by assessing 
IgG antibody to the SARS-CoV-2 spike 
protein (by ELISA), IgG antibody to the 
SARS-CoV-2 receptor-binding domain (by 
ELISA) and specific neutralizing antibody 
to SARS-CoV-2 (by classical in vitro 
neutralization assay) at 1 month, 6 months, 
12 months and 24 months after the first 
dose (Janssen vaccine) or second dose (all 
other vaccines) of the vaccine regimen (Fig. 
1). Secondary objectives will be to compare 
the kinetics and strength of the immune 
responses of each subpopulation (e.g., 
recipients of solid-organ transplantation) 
with those of the control group and to 
